APCCC 2024: In Patients with BCR and Positive Lesion(s) in the Pelvis – Stereotactic or Whole Pelvis Radiotherapy?
APCCC 2024 treatment for biochemical recurrence/PSA persistence, stereotactic or whole pelvis radiotherapy for patients with biochemical recurrence, APCCC key questions.